Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Marjolein van Ballegooijen
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Procedures
Disorders
Geographic Areas
Activities & Behaviors
Concepts & Ideas
Living Beings
Anatomy
Sign-in to see full Profile
Network (preview)
33
Habbema, Dik
15
van Oortmarssen, Gerrit
14
Boer, Rob
10
Rebolj, Matejka
6
Loeve, Franka
6
Koopmanschap, Marc
6
Bos, Anita
6
Zauber, Ann
6
van den Akker-van Marle, Elske
5
van Kemenade, Folkert
4
Snijders, Peter
4
Verheijen, René
4
Voorhorst, Feja
4
Helmerhorst, Theo
4
Kuipers, Ernst
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Marjolein van Ballegooijen (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Lansdorp-Vogelaar Iris; van Ballegooijen Marjolein; Zauber Ann G; Habbema J Dik F; Kuipers Ernst J
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Journal of the National Cancer Institute 2009;101(20):1412-22.
-
2009: Ronco Guglielmo; van Ballegooijen Marjolein; Becker Nikolaus; Chil Arkadiusz; Fender Muriel; Giubilato Pamela; Kurtinaitis Juozas; Lancucki Lesz; Lynge Elsebeth; Morais Antonio; O'Reilly Marian; Sparen Pär; Suteu Ofelia; Rebolj Matejka; Veerus Piret; Zakelj Maja Primic; Anttila Ahti
Process performance of cervical screening programmes in Europe.
European journal of cancer (Oxford, England : 1990) 2009;45(15):2659-70.
-
2009: de Kok Inge M C M; van Ballegooijen Marjolein; Habbema J Dik F
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Journal of the National Cancer Institute 2009;101(15):1083-92.
-
2009: Lansdorp-Vogelaar Iris; van Ballegooijen Marjolein; Zauber Ann G; Boer Rob; Wilschut Janneke; Winawer Sidney J; Habbema J Dik F
Individualizing colonoscopy screening by sex and race.
Gastrointestinal endoscopy 2009;70(1):96-108, 108.e1-24.
-
2009: Lansdorp-Vogelaar Iris; van Ballegooijen Marjolein; Boer Rob; Zauber Ann; Habbema J Dik F
A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials.
Cancer 2009;115(11):2410-9.
-
2009: de Kok I M C M; Polder J J; Habbema J D F; Berkers L-M; Meerding W J; Rebolj M; van Ballegooijen M
The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening.
British journal of cancer 2009;100(8):1240-4.
-
2009: Hol L; Wilschut J A; van Ballegooijen M; van Vuuren A J; van der Valk H; Reijerink J C I Y; van der Togt A C M; Kuipers E J; Habbema J D F; van Leerdam M E
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
British journal of cancer 2009;100(7):1103-10.
-
2009: Korfage Ida J; Essink-Bot Marie-Louise; Mols Floortje; van de Poll-Franse Lonneke; Kruitwagen Roy; van Ballegooijen Marjolein
Health-related quality of life in cervical cancer survivors: a population-based survey.
International journal of radiation oncology, biology, physics 2009;73(5):1501-9.
-
2009: Rebolj Matejka; van Ballegooijen Marjolein; Lynge Elsebeth; Looman Caspar; Essink-Bot Marie-Louise; Boer Rob; Habbema Dik
Incidence of cervical cancer after several negative smear results by age 50: prospective observational study.
BMJ (Clinical research ed.) 2009;338():b1354.
-
2008: Rebolj Matejka; van Ballegooijen Marjolein; van Kemenade Folkert; Looman Caspar; Boer Rob; Habbema J Dik F
No increased risk for cervical cancer after a broader definition of a negative Pap smear.
International journal of cancer. Journal international du cancer 2008;123(11):2632-5.
-
2008: Zauber Ann G; Lansdorp-Vogelaar Iris; Knudsen Amy B; Wilschut Janneke; van Ballegooijen Marjolein; Kuntz Karen M
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.
Annals of internal medicine 2008;149(9):659-69.
-
2008: van der Aa Maaike A; de Kok Inge M C M; Siesling Sabine; van Ballegooijen Marjolein; Coebergh Jan Willem W
Does lowering the screening age for cervical cancer in The Netherlands make sense?
International journal of cancer. Journal international du cancer 2008;123(6):1403-6.
-
2008: Korfage Ida J; Essink-Bot Marie-Louise; Daamen Ruth; Mols Floortje; van Ballegooijen Marjolein
Women show mixed intentions regarding the uptake of HPV vaccinations in pre-adolescents: a questionnaire study.
European journal of cancer (Oxford, England : 1990) 2008;44(9):1186-92.
-
2008: Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers E J
Screening for colorectal cancer: which test can we afford?
Zeitschrift für Gastroenterologie 2008;46 Suppl 1():S38-40.
-
2008: Dillner Joakim; Rebolj Matejka; Birembaut Philippe; Petry Karl-Ulrich; Szarewski Anne; Munk Christian; de Sanjose Silvia; Naucler Pontus; Lloveras Belen; Kjaer Susanne; Cuzick Jack; van Ballegooijen Marjolein; Clavel Christine; Iftner Thomas;
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
BMJ (Clinical research ed.) 2008;337():a1754.
-
2007: Bulkmans N W J; Berkhof J; Rozendaal L; van Kemenade F J; Boeke A J P; Bulk S; Voorhorst F J; Verheijen R H M; van Groningen K; Boon M E; Ruitinga W; van Ballegooijen M; Snijders P J F; Meijer C J L M
Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
Lancet 2007;370(9601):1764-72.
-
2007: Rebolj Matejka; Bais Aagje G; van Ballegooijen Marjolein; Boer Rob; Meerding Willem-Jan; Helmerhorst Theo J M; Habbema J Dik F
Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies.
International journal of cancer. Journal international du cancer 2007;121(7):1529-35.
-
2007: Berkers L M; van Ballegooijen M; van Kemenade F J; Rebolj M; Essink-Bot M L; Helmerhorst Th J M; Habbema J D F
[The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening]
Nederlands tijdschrift voor geneeskunde 2007;151(23):1288-94.
-
2007: Bais Aagje G; van Kemenade Folkert J; Berkhof Johannes; Verheijen René H M; Snijders Peter J F; Voorhorst Feja; Babovic Milena; van Ballegooijen Marjolein; Helmerhorst Theo J M; Meijer Chris J L M
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
International journal of cancer. Journal international du cancer 2007;120(7):1505-10.
-
2007: Rebolj Matejka; van Ballegooijen Marjolein; Berkers Louise-Maria; Habbema Dik
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands.
International journal of cancer. Journal international du cancer 2007;120(4):806-12.
-
2007: Ramsoekh D; van Leerdam M E; van Ballegooijen M; Habbema J D F; Kuipers E J
Population screening for colorectal cancer: faeces, endoscopes or X-rays?
Cellular oncology : the official journal of the International Society for Cellular Oncology 2007;29(3):185-94.
-
2006: Bos Anita B; Rebolj Matejka; Habbema J Dik F; van Ballegooijen Marjolein
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands.
International journal of cancer. Journal international du cancer 2006;119(10):2372-5.
-
2006: Vogelaar Iris; van Ballegooijen Marjolein; Schrag Deborah; Boer Rob; Winawer Sidney J; Habbema J Dik F; Zauber Ann G
How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment.
Cancer 2006;107(7):1624-33.
-
2005: Bais Aagje G; Rebolj Matejka; Snijders Peter J F; de Schipper Frits A; van der Meulen Dries A J; Verheijen René H M; Voorhorst Feja; van Ballegooijen Marjolein; Meijer Chris J L M; Helmerhorst Theo J M
Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines.
International journal of cancer. Journal international du cancer 2005;116(1):122-9.
-
2005: Loeve F; van Ballegooijen M; Snel P; Habbema J D F
Colorectal cancer risk after colonoscopic polypectomy: a population-based study and literature search.
European journal of cancer (Oxford, England : 1990) 2005;41(3):416-22.
-
2004: Loeve Franka; Boer Rob; Zauber Ann G; Van Ballegooijen Marjolein; Van Oortmarssen Gerrit J; Winawer Sidney J; Habbema J Dik F
National Polyp Study data: evidence for regression of adenomas.
International journal of cancer. Journal international du cancer 2004;111(4):633-9.
-
2004: Loeve F; van Ballegooijen M; Boer R; Kuipers E J; Habbema J D F
Colorectal cancer risk in adenoma patients: a nation-wide study.
International journal of cancer. Journal international du cancer 2004;111(1):147-51.
-
2004: Bulkmans Nicole W J; Rozendaal Lawrence; Snijders Peter J F; Voorhorst Feja J; Boeke A Joan P; Zandwijken Gladys R J; van Kemenade Folkert J; Verheijen René H M; v Groningen Krijn; Boon Mathilde E; Keuning Hans J F; van Ballegooijen Marjolein; van den Brule Adriaan J C; Meijer Chris J L M
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
International journal of cancer. Journal international du cancer 2004;110(1):94-101.
-
2003: van den Akker-van Marie M E; van Ballegooijen M; Rozendaal L; Meijer C J L M; Habbema J D F
Extended duration of the detectable stage by adding HPV test in cervical cancer screening.
British journal of cancer 2003;89(10):1830-3.
-
2003: van den Akker-van Marle M E; van Ballegooijen M; Habbema J D F
Low risk of cervical cancer during a long period after negative screening in the Netherlands.
British journal of cancer 2003;88(7):1054-7.
-
2002: Meerding Willem Jan; van Ballegooijen Marjolein; Burger Matthé P M; van den Akker-van Marle M Elske; Quint Wim G V; Habbema J Dik F
Human papillomavirus testing for triage of women referred because of abnormal smears. a decision analysis considering outcomes and costs.
Journal of clinical epidemiology 2002;55(10):1025-32.
-
2002: Bos A B; van Ballegooijen M; van den Akker-van Marle M E; Habbema J D F
[Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996]
Nederlands tijdschrift voor geneeskunde 2002;146(34):1586-90.
-
2002: Bos A B; van Ballegooijen M; van Oortmarssen G J; Habbema J D F
Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening.
European journal of cancer (Oxford, England : 1990) 2002;38(6):827-31.
-
2002: van den Akker-van Marle M Elske; van Ballegooijen Marjolein; van Oortmarssen Gerrit J; Boer Rob; Habbema J Dik F
Cost-effectiveness of cervical cancer screening: comparison of screening policies.
Journal of the National Cancer Institute 2002;94(3):193-204.
-
2001: Bos A B; van Ballegooijen M; Elske van den Akker-van Marle M; Hanselaar A G; van Oortmarssen G J; Habbema J D
Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears.
American journal of clinical pathology 2001;115(6):851-5.
-
2001: Loeve F; Boer R; van Oortmarssen G J; van Ballegooijen M; Habbema J D
Impact of systematic false-negative test results on the performance of faecal occult blood screening.
European journal of cancer (Oxford, England : 1990) 2001;37(7):912-7.
-
2001: Meerding W J; Doornewaard H; van Ballegooijen M; Bos A; van der Graaf Y; van den Tweel J G; van der Schouw Y T; Habbema J D
Cost analysis of PAPNET-assisted vs. conventional Pap smear evaluation in primary screening of cervical smears.
Acta cytologica 2001;45(1):28-35.
-
2000: van Ballegooijen M; Hermens R
Cervical cancer screening in the Netherlands.
European journal of cancer (Oxford, England : 1990) 2000;36(17):2244-6.
-
2000: van Ballegooijen M; van den Akker-van Marle E; Patnick J; Lynge E; Arbyn M; Anttila A; Ronco G; Dik J; Habbema F
Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness.
European journal of cancer (Oxford, England : 1990) 2000;36(17):2177-88.
-
2000: Cuzick J; Sasieni P; Davies P; Adams J; Normand C; Frater A; van Ballegooijen M; van den Akker-van Marle E
A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions.
British journal of cancer 2000;83(5):561-5.
-
2000: Loeve F; Brown M L; Boer R; van Ballegooijen M; van Oortmarssen G J; Habbema J D
Endoscopic colorectal cancer screening: a cost-saving analysis.
Journal of the National Cancer Institute 2000;92(7):557-63.
-
1999: van den Akker-van Marle M E; van Ballegooijen M; Boer R; van Oortmarssen G J; Habbema J D
Withdrawing low risk women from cervical screening programmes. Conclusions cannot yet be drawn.
BMJ (Clinical research ed.) 1999;319(7201):58.
-
1999: Kreuger F A; van Ballegooijen M; Doornewaard H
Is PAPNET suitable for primary screening?
Lancet 1999;353(9162):1374-5.
-
1999: Loeve F; Boer R; van Oortmarssen G J; van Ballegooijen M; Habbema J D
The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening.
Computers and biomedical research, an international journal 1999;32(1):13-33.
-
1999: Cuzick J; Sasieni P; Davies P; Adams J; Normand C; Frater A; van Ballegooijen M; van den Akker E
A systematic review of the role of human papillomavirus testing within a cervical screening programme.
Health technology assessment (Winchester, England) 1999;3(14):i-iv, 1-196.
-
1998: Bos A B; van Ballegooijen M; van Gessel-Dabekaussen A A; Habbema J D
Organised cervical cancer screening still leads to higher coverage than spontaneous screening in The Netherlands.
European journal of cancer (Oxford, England : 1990) 1998;34(10):1598-601.
-
1998: van Ballegooijen M; Beck S; Boon M E; Boer R; Habbema J D
Rescreen effect in conventional and PAPNET screening: observed in a study using material enriched with positive smears.
Acta cytologica 1998;42(5):1133-8.
-
1998: Kreuger F A; Beerman H; Nijs H G; van Ballegooijen M
Positive diagnostic values and histological detection ratios from the Rotterdam cervical cancer screening programme.
International journal of epidemiology 1998;27(3):377-81.
-
1997: van Ballegooijen M; van den Akker-van Marle M E; Warmerdam P G; Meijer C J; Walboomers J M; Habbema J D
Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness.
British journal of cancer 1997;76(5):651-7.
-
1997: Bos A B; van Ballegooijen M; van Oortmarssen G J; van Marle M E; Habbema J D; Lynge E
Non-progression of cervical intraepithelial neoplasia estimated from population-screening data.
British journal of cancer 1997;75(1):124-30.
-
1995: van Ballegooijen M; Koopmanschap M A; Habbema J D
The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands.
European journal of cancer (Oxford, England : 1990) 1995;31A(10):1672-6.
-
1992: van Oortmarssen G J; Habbema J D; van Ballegooijen M
Predicting mortality from cervical cancer after negative smear test results.
BMJ (Clinical research ed.) 1992;305(6851):449-51.
-
1992: van Ballegooijen M; Habbema J D; van Oortmarssen G J; Koopmanschap M A; Lubbe J T; van Agt H M
Preventive Pap-smears: balancing costs, risks and benefits.
British journal of cancer 1992;65(6):930-3.
-
1992: van Ballegooijen M; Koopmanschap M A; Tjokrowardojo A J; van Oortmarssen G J
Care and costs for advanced cervical cancer.
European journal of cancer (Oxford, England : 1990) 1992;28A(10):1703-8.
-
1990: Koopmanschap M A; van Oortmarssen G J; van Agt H M; van Ballegooijen M; Habbema J D; Lubbe K T
Cervical-cancer screening: attendance and cost-effectiveness.
International journal of cancer. Journal international du cancer 1990;45(3):410-5.
-
1990: van Ballegooijen M; Koopmanschap M A; van Oortmarssen G J; Habbema J D; Lubbe K T; van Agt H M
Diagnostic and treatment procedures induced by cervical cancer screening.
European journal of cancer (Oxford, England : 1990) 1990;26(9):941-5.
-
1990: Koopmanschap M A; Lubbe K T; van Oortmarssen G J; van Agt H M; van Ballegooijen M; Habbema J K
Economic aspects of cervical cancer screening.
Social science & medicine (1982) 1990;30(10):1081-7.
Sign-in to see more
